Navigation Links
Quark Pharmaceuticals and Major Pharmaceutical Company Enter into Licensing Option Agreement for the p53 Suppressor Drug QPI-1002, the First siRNA Administered Systemically in Human
Date:8/18/2010

eserve RNAi activity while ameliorating potential off-target and immunostimulatory effects of siRNAs.

Quark is also committed to leveraging a broad research pipeline of siRNA drug candidates and novel siRNA structures to develop additional RNAi drug candidates.

Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel. Additional information is available at www.quarkpharma.com.Quark Pharmaceuticals, Inc.The Ruth Group (investors / media)Juliana Friedman

Sara Pellegrino / Jason Rando+972 89 30 5111

(646) 536-7002 / 7025jfriedman@quarkpharma.com

spellegrino@theruthgroup.comjrando@theruthgroup.com
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 2014  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced ... of common stock and warrants at a price of ... prior to deducting underwriting discounts and commissions and offering ... are immediately separable and will be issued separately.  The ... on The NASDAQ Stock Market under the ticker symbol ...
(Date:8/21/2014)... --  Memorial Hermann Health System and The University ... new partnership to provide a new level of specialized breast ... the greater Houston area. ... provider of professional breast radiology services for five of Memorial ... The Woodlands , Northeast, Southwest and ...
(Date:8/21/2014)... , Aug. 21, 2014 Nektar ... International Inc. today announced positive results from its ... an investigational, extended half-life recombinant factor VIII (rFVIII) ... Factor (Recombinant)], which met its primary endpoint in ... arm compared to the on-demand arm. ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
... Johnson & Johnson Pharmaceutical,Research & Development, ... demonstrate doripenem (DORIBAX(TM), doripenem for injection), a,carbapenem ... in vitro against certain,strains of Enterobacteriaceae, including ... Enterobacteriaceae is a large group of ...
... A doctor who is,internationally recognized for her ... DHA, an omega-3 fatty acid, has received the,March ... in the field,of maternal-fetal nutrition., Susan E. ... that infants,receiving breast milk had higher DHA (dietary ...
Cached Medicine Technology:New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 2New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 3New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 4New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 5March of Dimes Honors Dr. Susan Carlson for Outstanding Work In Maternal-Fetal Nutrition 2
(Date:8/23/2014)... (PRWEB) August 23, 2014 GranuFlo ... 2012 GranuFlo and NaturaLyte dialysis concentrate recall continue ... in U.S. District Court, District of Massachusetts, Bernstein ... report issued by the U.S. Judicial Panel on ... 2,028 claims are pending in the proceeding. In ...
(Date:8/23/2014)... 2014 According to the new ... Application and Geography - Regional Trends & Forecast ... Market with an analysis and forecast of value ... of electronic adhesives by applications and geography are ... market data tables and 26 figures spread through ...
(Date:8/23/2014)... PA (PRWEB) August 23, 2014 "When ... sometimes comes into contact with the dirty water inside ... the seat itself," said one of two inventors from ... to germs, we developed this protective device." , They ... unsanitary toilet surfaces, including the water, bowl and seat. ...
(Date:8/23/2014)... 2014 Hundreds of Wright hip ... of individuals who were allegedly harmed by devices ... to move forward in the U.S. District Court, ... According to an Order dated August 19th, the ... would allow the litigation’s first case to go ...
(Date:8/23/2014)... York, NY (PRWEB) August 23, 2014 ... (NYT) reported on a data breach suffered by ... that saw the compromise of 4.5 million records containing ... social security numbers. According to Mandiant, who was engaged ... emanated from an advanced group of cyber attackers ...
Breaking Medicine News(10 mins):Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Mount in Federal Litigation, as Filings Surpass 2,000, Bernstein Liebhard LLP Reports 4Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4
... cells to spread from a primary site, to form ... process in which cell motility and invasion play a ... develops is identification of the molecules, and characterisation of ... mechanisms have been poorly understood. Now, a team of ...
... with diabetes have the weight-loss surgery? , , SUNDAY, Dec. ... bypass surgery extends the lives of obese patients is ... go under the knife and who shouldn,t. , ... patients who traditionally haven,t been candidates for the weight-loss ...
... breast cancer prevention study using exemestane (Aromasin) finds an ... II study details reported today, by Jennifer Eng-Wong, MD, ... Center at the San Antonio Breast Cancer Symposium, examines ... at an increased risk of developing breast cancer based ...
... transcript of President Bush,s weekly radio address to the nation: , ... week, our country received good news in the fight against illegal drugs. ... to decline -- and that we are making good progress in our ... , , Substance abuse is a serious ...
... leading healthcare provider of interim and executive placement and consulting solutions, ... board and CEO services. Formerly vice president, senior executive search, Noland ... for hospitals, home care companies, health systems and national healthcare organizations. ... ...
... retail locations joining national partners in effort to raise $5 ... Dec. 12 National partners from the 17th annual ... Memphis today to celebrate raising more than $2.4 million to ... , , Companies represented at ...
Cached Medicine News:Health News:Gastric Bypass Success Sparks Debate 2Health News:Gastric Bypass Success Sparks Debate 3Health News:Radio Address by President Bush to the Nation 2Health News:Radio Address by President Bush to the Nation 3Health News:Noland Named Vice President, Board & CEO Services for B. E. Smith 2Health News:More Than $2.4 Million Raised by National Halloween Promotion Partners to Help St. Jude Fight Childhood Cancer 2
Platelet agitator....
I-125 competitive RIA kit for the detection of Progesterone....
... quantitative determination of progesterone ... Progesterone EIA is ... of competitive binding between ... specimen and progesterone-HRP conjugate ...
ELISA for the detection of Insulin....
Medicine Products: